Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,895.85 +18.80 (+0.24%) Bitcoin USD
63,945.60 +809.83 (+1.28%) CMC Crypto 200
1,376.08 +63.46 (+4.84%)
BeyondSpring Inc. (BYSI)
| Previous close | 1.8000 |
| Open | 1.8000 |
| Bid | 1.8200 x 100 |
| Ask | 1.9600 x 100 |
| Day's range | 1.8000 - 1.9680 |
| 52-week range | 0.6530 - 4.0000 |
| Volume | |
| Avg. volume | 226,224 |
| Market cap | 74.52M |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7100 |
| Earnings date | 19 Apr 2024 - 24 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.25 |
GlobeNewswireBeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
FLORHAM PARK, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that the first patient has been dosed in a Phase 2 investigator-initiated trial (IIT) with Pembrolizumab, Plinabulin, BeyondSpring’s lead asset, plus Etoposide/Platinum (EP) for first-line (1L) Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) [NCT05745350]. Cu
Simply Wall St.Retail investors invested in BeyondSpring Inc. (NASDAQ:BYSI) up 125% last week, insiders too were rewarded
Key Insights Significant control over BeyondSpring by retail investors implies that the general public has more power...
- GlobeNewswire
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
FLORHAM PARK, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that on February 20, 2024, the Company received a written notification on minimum bid price compliance (the “Notification Letter”)
